Residual tricuspid regurgitation after transcatheter tricuspid valve edge-to-edge repair: the EuroTR Registry
Abstract Background Data on the prognostic impact of residual tricuspid regurgitation (TR) after transcatheter tricuspid valve edge-to-edge repair (T-TEER) are scarce. Purpose The aim of this analysis was to evaluate two-year survival and symptomatic outcomes of patients in relation to residual TR after T-TEER. Methods Using the large European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR Registry) we investigated the impact of residual TR on two-year all-cause mortality and New York Heart Association (NYHA) functional class at follow-up. The study further identified predictors for residual TR ≥3+ using a logistic regression model. Results The study included a total of 1286 T-TEER patients (53.6% females, mean age 78.0 ± 8.9 years). TR was successfully reduced to ≤1+ in 42.4%, 2+ in 40.0% and 3+ in 14.9% of patients at discharge, while 2.8% remained with TR ≥4+ after the procedure. Residual TR ≥3+ was an independent multivariable predictor of two-year all-cause mortality (hazard ratio 2.06, confidence interval 1.30-3.26, p=0.002, Figure 1). The prevalence of residual TR ≥3+ was 4-times higher in patients with higher baseline TR (vena contracta > 11.1 mm) and more severe TV tenting (tenting area >1.92 cm2) (Figure 2). Of note, no survival difference was observed in patients with residual TR ≤1+ vs. 2+ (76.2% vs. 73.1%, p=0.461). The rate of NYHA functional class ≥ III at follow-up was significantly higher in patients with residual TR ≥3+ (52.4% vs. 40.5%, p<0.001). Of note, the degree of TR reduction significantly correlated with the extend of symptomatic improvement (p=0.012). Conclusions T-TEER effectively reduced TR severity in the majority of patients. While residual TR ≥3+ was associated with worse outcomes, no differences were observed for residual TR 1+ vs. 2+. Symptomatic improvement correlated with the degree of TR reduction.Figure 1- Residual TR after T-TEERFigure 2 - Predicting residual TR
Authors
- Christos Iliadis (ORCID: https://orcid.org/0000-0001-7655-8500)
- Volker Rudolph (ORCID: https://orcid.org/0000-0001-5385-6839)
- Francesco Maisano (ORCID: https://orcid.org/0000-0002-3691-1709)
- Rodrigo Estévez‐Loureiro (ORCID: https://orcid.org/0000-0001-5841-5514)
- Nicole Karam (ORCID: https://orcid.org/0000-0002-3861-6914)
- Peter Luedike
- Hölger Thiele (ORCID: https://orcid.org/0000-0002-0169-998X)
- Fabien Praz (ORCID: https://orcid.org/0000-0001-5416-165X)
- Mirjam Keßler (ORCID: https://orcid.org/0000-0001-6423-0508)
- Jörg Hausleiter (ORCID: https://orcid.org/0000-0003-2909-7961)
- Marco Metra (ORCID: https://orcid.org/0000-0001-6691-8568)
- Lukas Stolz (ORCID: https://orcid.org/0000-0002-1362-1493)
- D Kalbacher
- Philipp Lurz (ORCID: https://orcid.org/0000-0002-5993-4487)
- Philipp Lauten (ORCID: https://orcid.org/0000-0001-9997-9201)
Institutions
- University of Bern (CH)
- Johannes Gutenberg University Mainz (DE)
- Heart and Diabetes Center North Rhine-Westphalia (DE)
- University Hospital of Bern (CH)
- University Hospital Complex Of Vigo (ES)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Zentralklinik Bad Berka (DE)
- Leipzig Heart Institute (DE)
- Essen University Hospital (DE)
- European Hospital (IT)
- University Hospital Cologne (DE)
- University Hospital Ulm (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/eurheartj/ehae666.1933
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.40